CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients

Høgdall, Estrid; Christensen, Lise; Kjær, Susanne K.; Blaakær, Jan; Kjærbye‐Thygesen, Anette; Gayther, Simon A.; Jacobs, Ian; Høgdall, Claus

doi:10.1016/j.ygyno.2006.09.028

Cited by 125 publications

(108 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2e), even though relatively low levels of serum CA125 have been reported in these populations. [22][23][24][25] As the mesothelin-binding ability of CA125 is a key factor for the CA125 meso assay, the difference in CA125 meso /CA125 levels between patients with endometriosis and EOC implies that this assay may have an advantage over the conventional antibody-based CA125 assay for a differential diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Difference in mesothelin‐binding ability of serum CA125 between patients with endometriosis and epithelial ovarian cancer

Sasaki

Akita

Ito

et al. 2014

Intl Journal of Cancer

View full text Add to dashboard Cite

The epithelial ovarian carcinoma (EOC) is an aggressive malignant tumor, and is currently the leading cause of gynecologic cancer death. CA125 is the most commonly used serum marker for EOC, but shows a high-false-positive rate for several benign diseases such as endometriosis. The purpose of our study is therefore to identify a useful biochemical tool for detecting qualitative differences between CA125 from patients with endometriosis and EOC, and to facilitate differential diagnosis of these diseases. In our study, using two different CA125-binding molecules, i.e., recombinant mesothelin and an anti-CA125 monoclonal antibody, a novel sandwich ELISA for determining the serum levels of CA125 with mesothelin-binding ability (CA125 meso ) was developed, and tested for patients with endometriosis (n 5 59) and EOC (n 5 36). We found that both the serum CA125 meso level and the ratio of the serum CA125 meso to CA125 levels (CA125 meso /CA125) were significantly higher in patients with EOC than in patients with endometriosis (p < 0.00005 and p < 0.000001, respectively). Furthermore, receiver operating characteristic analysis showed that the CA125 meso assay was superior to the conventional antibody-based CA125 assay in discriminating endometriosis from EOC. Thus, mesothelin-binding ability may be a useful indicator for qualitatively evaluating CA125 in patients with endometriosis and EOC.

show abstract

Section: Discussionmentioning

confidence: 99%

Difference in mesothelin‐binding ability of serum CA125 between patients with endometriosis and epithelial ovarian cancer

Sasaki

Akita

Ito

et al. 2014

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Limited expression of MUC16 in mucinous EOC has also been reported by other groups (de la Cuesta et al, 1999). These authors also showed that MUC16 tissues expression was significantly correlated with the FIGO stage but not with the histological grade (Hogdall et al, 2007). In another study using tissues arrays, Rao et al, found that 56%-66% of serous high grade EOC expressed MUC16 depending on the antibody used (OC125 vs 4H11) (Rao et al, 2010).…”

Section: Expression Of Muc16 In Normal Tissues and Ovarian Tumorsmentioning

confidence: 51%

“…The expression of MUC16 in EOC tissues varies according to the histotype. Using tissues arrays, Hogdall et al, reported that MUC16 was expressed by 85% of serous, 65% of endometrioid, 40% of clear cell and 36% of undifferentiated adenocarcinomas, but by only 12% of mucinous cancers (Hogdall et al, 2007). Limited expression of MUC16 in mucinous EOC has also been reported by other groups (de la Cuesta et al, 1999).…”

Section: Expression Of Muc16 In Normal Tissues and Ovarian Tumorsmentioning

confidence: 75%

“…de la Cuesta et al, found that, in a cohort of 50 EOC samples, patients with high tissue expression of MUC16 had a higher risk of death compared to patients with no expression (de la Cuesta et al, 1999). However, in a much larger cohort of 778 EOC samples, Hogdall et al, showed that latestage patients that lacked MUC16 tissue expression had a significantly poorer survival (Hogdall et al, 2007). In addition, MUC16 expression had no prognostic value in early stage EOC (Hogdall et al, 2007).…”

Section: Expression Of Muc16 In Normal Tissues and Ovarian Tumorsmentioning

confidence: 99%

See 1 more Smart Citation

The Role of MUC16 Mucin (CA125) in the Pathogenesis of Ovarian Cancer

Rancourt¹,

Matte²,

Lane³

et al. 2012

Ovarian Cancer - Basic Science Perspective

View full text Add to dashboard Cite

“…Its serum concentration correlates with the mass of living tumor cells [3,4]. The reference value for suspicion of epithelial ovarian cancer (EOC) is <35 U/ml.…”

Section: Introductionmentioning

confidence: 99%

Preoperative measurement of serum CA-125 levels: is it useful in the risk assessment of low volume lymph node disease in cervical cancer?

Śniadecki

Wojtylak

Wycinka

et al. 2017

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

show abstract

CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients

Cited by 125 publications

References 24 publications

Difference in mesothelin‐binding ability of serum CA125 between patients with endometriosis and epithelial ovarian cancer

Difference in mesothelin‐binding ability of serum CA125 between patients with endometriosis and epithelial ovarian cancer

The Role of MUC16 Mucin (CA125) in the Pathogenesis of Ovarian Cancer

Preoperative measurement of serum CA-125 levels: is it useful in the risk assessment of low volume lymph node disease in cervical cancer?

Contact Info

Product

Resources

About